FeesSafety
Pluang+

Keplr wallet suspends Google and Apple logins after $6M Cosmos transfers from Web3Auth breach

Market News
08 Nov 2026, 20:30 WIB
Bitcoin
View Source
Bearish
Keplr wallet suspends Google and Apple logins after $6M Cosmos transfers from Web3Auth breach

A security flaw in Web3Auth exposed private keys, forcing Keplr to disable Google and Apple logins to prevent further unauthorized transactions. Blockchain analysis traced over $6 million transferred across Cosmos networks, but some movements were protective recovery efforts, not theft. Recovery-phrase and hardware-wallet users remain safe, while Keplr and Web3Auth work to secure affected social-login wallets. Users are advised to move assets to new wallets and avoid deposits until the issue is fully resolved.

Keplr Wallet breach is the story subject, here is Pluang's market snapshot as of Nov 09, 2026 01:02 WIB: Among 50 major cryptocurrencies, 8 rose and 40 fell. ZIL traded at Rp30 with a 4.27% decline and 74% sell order activity. KSM was priced at Rp56,574, down 4.17%, with a typical hold time of 81 days. THETA stood at Rp2,532, down 4.09%, with 79% buy order activity and a typical hold time of 78 days.

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
3 hours ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
3 hours ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
3 hours ago
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
Bullish
3 hours ago
Lumens (XLM) futures open interest shifts amid upcoming Bell upgrade vote on Nov 23

Lumens (XLM) futures open interest shifts amid upcoming Bell upgrade vote on Nov 23

Lumens (XLM) futures open interest recently changed from about $94 million to $88 million, then rose slightly to $89.5 million. The positive funding rate was 0.0011%. The key event is the upcoming Bell upgrade for Stellar's protocol, which passed a t...

Protocol Fundamentals
Neutral
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App